Boston Partners lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,368,759 shares of the medical research company's stock after selling 97,257 shares during the period. IQVIA accounts for about 1.0% of Boston Partners' investment portfolio, making the stock its 15th biggest holding. Boston Partners owned approximately 2.65% of IQVIA worth $1,172,809,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also bought and sold shares of IQV. Meeder Asset Management Inc. raised its position in shares of IQVIA by 1,518.8% in the 3rd quarter. Meeder Asset Management Inc. now owns 3,788 shares of the medical research company's stock worth $1,018,000 after acquiring an additional 3,554 shares in the last quarter. Harbour Wealth Management Group Inc. grew its stake in IQVIA by 7.1% in the third quarter. Harbour Wealth Management Group Inc. now owns 3,071 shares of the medical research company's stock valued at $826,000 after purchasing an additional 203 shares during the last quarter. Composition Wealth LLC purchased a new position in IQVIA in the third quarter valued at about $257,000. Voya Investment Management LLC grew its stake in IQVIA by 236.2% in the third quarter. Voya Investment Management LLC now owns 177,549 shares of the medical research company's stock valued at $47,734,000 after purchasing an additional 124,739 shares during the last quarter. Finally, Global Retirement Partners LLC raised its holdings in IQVIA by 55.9% in the third quarter. Global Retirement Partners LLC now owns 11,189 shares of the medical research company's stock worth $3,008,000 after purchasing an additional 4,010 shares in the last quarter. Institutional investors own 89.62% of the company's stock.
Insider Transactions at IQVIA
In other IQVIA news, insider Eric Sherbet sold 4,446 shares of IQVIA stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $278.83, for a total transaction of $1,239,678.18. Following the completion of the transaction, the insider owned 24,989 shares in the company, valued at approximately $6,967,682.87. This trade represents a 15.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider James G. Berkshire sold 2,668 shares of the business's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the transaction, the insider directly owned 10,890 shares of the company's stock, valued at approximately $2,845,883.70. This trade represents a 19.68% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 1.70% of the company's stock.
Analyst Upgrades and Downgrades
IQV has been the topic of a number of recent analyst reports. Robert W. Baird raised their price target on shares of IQVIA from $324.00 to $328.00 and gave the company an "outperform" rating in a report on Tuesday, October 27th. HSBC upped their price target on IQVIA from $280.00 to $300.00 and gave the stock a "buy" rating in a research report on Tuesday, September 1st. Jefferies Financial Group increased their price objective on shares of IQVIA from $220.00 to $290.00 and gave the company a "buy" rating in a research report on Wednesday, July 29th. Mizuho upped their target price on IQVIA from $275.00 to $300.00 and gave the company an "outperform" rating in a research report on Wednesday, October 7th. Finally, Weiss Ratings lowered IQVIA from a "hold (c+)" rating to a "sell (d+)" rating in a research note on Wednesday, October 28th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $294.21.
Read Our Latest Analysis on IQV
IQVIA Stock Up 0.1%
IQV stock opened at $257.97 on Thursday. The company has a market capitalization of $42.51 billion, a P/E ratio of 31.35, a price-to-earnings-growth ratio of 2.29 and a beta of 1.16. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $284.50. The firm's fifty day simple moving average is $267.49 and its 200-day simple moving average is $212.26. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.83 and a quick ratio of 0.83.
IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.26 by $0.08. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The firm had revenue of $4.43 billion during the quarter, compared to analysts' expectations of $4.37 billion. During the same quarter last year, the company posted $3.00 earnings per share. The firm's revenue was up 8.0% compared to the same quarter last year. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 11.53 earnings per share for the current year.
About IQVIA
(
Free Report)
IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company's offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.